Cargando…

Clinical utility of serum folate measurement in tertiary care patients: Argument for revising reference range for serum folate from 3.0 ng/mL to 13.0 ng/mL

OBJECTIVE: Assess the need for folate testing, frequency of corrective action, and determine reference level for serum folate. METHODS: Serum folate levels in 5313 samples from 4448 patients, and clinical data were reviewed for patient characteristics and for (a) evidence of corrective action in pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Gurmukh, Hamdan, Hana, Singh, Vivek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5597708/ https://www.ncbi.nlm.nih.gov/pubmed/28932797 http://dx.doi.org/10.1016/j.plabm.2015.03.005

Ejemplares similares

The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
por: Adegun, Patrick Temi, et al.
Publicado: (2015)

Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng/mL
por: Ahn, Jae Hyun, et al.
Publicado: (2014)

Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
por: Chung, Jae Hoon, et al.
Publicado: (2020)

Pathological characteristics and predictive factors of prostate biopsy in patients with serum PSA levels between 0 and 4.0 ng/ml
por: Su, Rui, et al.
Publicado: (2022)

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?
por: Lee, Seung Hwan, et al.
Publicado: (2011)

Low Expectancy of Conversion Surgery with R0 Resection in Patients with CEA > 5.0 ng/mL at the Initial RECIST Evaluation for Metastatic Gastric Cancer
por: Nakanishi, Koki, et al.
Publicado: (2023)

Biparametric MRI-based radiomics classifiers for the detection of prostate cancer in patients with PSA serum levels of 4∼10 ng/mL
por: Lu, Yangbai, et al.
Publicado: (2022)

Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL
por: Hinev, Alexander I., et al.
Publicado: (2012)

Prognosis of prostate cancer with initial prostate-specific antigen >1,000 ng/mL at diagnosis
por: Kan, Hung-Cheng, et al.
Publicado: (2017)

A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL
por: Miyoshi, Yasuhide, et al.
Publicado: (2022)

Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range
por: Vukovic, I., et al.
Publicado: (2017)

No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study)
por: Ku, Cheol Ryong, et al.
Publicado: (2016)

PSA density improves the rate of prostate cancer detection in Chinese men with a PSA between 2.5–10.0 ng ml(-1) and 10.1–20.0 ng ml(-1): a multicenter study
por: Lin, Yu-Rong, et al.
Publicado: (2015)

Association of Nadir Prostate-specific Antigen >0.5 ng/mL after Dose-escalated External Beam Radiation with Prostate Cancer-specific Endpoints
por: Sheth, Niki, et al.
Publicado: (2018)

Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostate-specific antigen levels of 4–10 ng/mL
por: Chen, Na, et al.
Publicado: (2017)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Development and validation of a nomogram for predicting prostate cancer in patients with PSA ≤ 20 ng/mL at initial biopsy
por: Wu, Qiang, et al.
Publicado: (2021)

Correlation of Serum Androgens and Pituitary Hormone Levels with Serum PSA Less Than 2.5 NG/ML
por: Sofikerim, Mustafa, et al.
Publicado: (2007)

Evidence That Increasing Serum 25(OH)D Concentrations to 30 ng/mL in the Kingdom of Saudi Arabia and the United Arab Emirates Could Greatly Improve Health Outcomes
por: Grant, William B., et al.
Publicado: (2023)

The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria
por: Ezenwa, E.V., et al.
Publicado: (2012)

Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA
por: Zhao, Jing, et al.
Publicado: (2016)

Ocular Tolerability of Bimatoprost 0.1 mg/mL Preservative-Free versus Bimatoprost 0.1 mg/mL with Benzalkonium Chloride or Bimatoprost 0.3 mg/mL Preservative-Free in Patients with Primary Open-Angle Glaucoma
por: Filippelli, Mariaelena, et al.
Publicado: (2022)

Comparison of prostate cancer detection rates of various prostate biopsy methods for patients with prostate-specific antigen levels of <10.0 ng/mL in real-world practice
por: Oh, Kyung Tak, et al.
Publicado: (2020)

Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0–10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium
por: Chen, Rui, et al.
Publicado: (2015)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
por: Fiamegos, Alexandros, et al.
Publicado: (2016)

The diagnostic effectiveness of serum sialic acid predicts both qualitative and quantitative prostate cancer in patients with prostate-specific antigen between 4 and 20 ng/mL
por: Sun, Jingtao, et al.
Publicado: (2023)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

Urinary Biomarker Panel to Improve Accuracy in Predicting Prostate Biopsy Result in Chinese Men with PSA 4–10 ng/mL
por: Zhou, Yongqiang, et al.
Publicado: (2017)

Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?
por: Koc, Gokhan, et al.
Publicado: (2017)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

Bioavailability study of Enoxaparin Sodium Chemi (80 mg/0.8 mL) and Clexane (80 mg/0.8 mL) subcutaneous injection in healthy adults
por: Febbraro, Salvatore, et al.
Publicado: (2021)

‘Walking epidural’: comparison of the analgesic efficacy of levobupivacaine 0.0625% + fentanyl 2mcg/mL versus ropivacaine 0.075% + fentanyl 2mcg/mL
por: Mingote, Álvaro, et al.
Publicado: (2023)

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection
por: Maghbooli, Zhila, et al.
Publicado: (2020)

AB013. The study on the diagnostic value of f/tPSA to the prostate cancer with tPSA greater than 10 ng/mL
por: Li, Yan-Feng, et al.
Publicado: (2016)

Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection
por: Zheng, Yuxiao, et al.
Publicado: (2016)

Comparison of Multiparametric and Biparametric MRI in First Round Cognitive Targeted Prostate Biopsy in Patients with PSA Levels under 10 ng/mL
por: Lee, Dong Hoon, et al.
Publicado: (2017)

Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients
por: Jung, Hee-Yeon, et al.
Publicado: (2020)

Prostate cancer incidence in men with prostate‐specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer
por: Ola, Idris Olasunmbo, et al.
Publicado: (2022)

Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with PSA levels between 2.6 and 10.0 ng/mL
por: Castro, Hugo A. Socrates, et al.
Publicado: (2018)

Editorial comment to “The value of percentage free prostate-specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0–10.0 ng/mL) in Nigeria” and Reply by authors
por: Elabbady, Ahmed, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_7flh2mvo7ld6df57o01j44dio3